Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains?Zacks Investment Research • 10/03/25
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From NowThe Motley Fool • 09/26/25
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's WhyZacks Investment Research • 09/22/25
Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/09/25
Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference TranscriptSeeking Alpha • 09/03/25
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have TodayThe Motley Fool • 08/29/25
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to SellThe Motley Fool • 08/25/25
Is Recursion Pharmaceuticals (RXRX) Nvidia's Key AI Biotech Stake a Buy Amid Innovation Surge?24/7 Wall Street • 08/08/25
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/05/25
Recursion Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/25
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5thGlobeNewsWire • 07/29/25